A promising experimental antibody targeting pancreatic cancer has shown encouraging results in an early-phase clinical trial conducted at Grenoble-Alpes University Hospital (CHU Grenoble-Alpes), according to recent reports from French research institutions. The treatment, developed by scientists at the Léon Bérard Cancer Center in Lyon and the French National Centre for Scientific Research (CNRS), aims to overcome a key mechanism of treatment resistance in pancreatic tumors.
The antibody, named NP137, was evaluated in a phase 1b clinical trial coordinated by the digestive oncology team at Grenoble-Alpes University and CHU Grenoble-Alpes, with financial support from the ARC Foundation and the biotech startup NTRIS Pharma. Results published in April 2026 indicate that the therapy improved response to chemotherapy and increased survival in patients with locally advanced, initially inoperable pancreatic cancer.
Pancreatic cancer remains one of the deadliest malignancies due to its aggressive nature and frequent resistance to standard treatments like chemotherapy. Researchers identified that some cancer cells evade treatment by reactivating a developmental protein called netrin-1, which is normally active only during embryonic growth but becomes abnormally expressed in tumors. This reactivation promotes epithelial-mesenchymal transition, a process that enhances cancer cell invasiveness and resistance to therapy.
NP137 is designed to block the interaction between netrin-1 and its receptors on cancer cells, thereby inhibiting this resistance pathway. Preclinical studies by the research team led by Patrick Mehlen at the Léon Bérard Center demonstrated that targeting netrin-1 could restore sensitivity to chemotherapy in resistant cancer models.
The clinical trial assessed the safety and preliminary efficacy of NP137 when combined with standard chemotherapy. According to the CNRS press release dated April 22, 2026, the combination not only improved chemotherapy response but similarly contributed to increased survival in the trial cohort, although specific survival statistics were not disclosed in the available reports.
The trial was made possible through funding from the ARC Foundation, a major French cancer research charity, and collaboration between academic hospitals and research centers in Grenoble and Lyon. The results were shared in a press release by the Rhône-Auvergne delegation of the CNRS and later covered by regional media outlets, including Actu.fr, which reported on the successful testing of the medication at CHU Grenoble-Alpes on April 25, 2026.
Even as the findings are preliminary and based on an early-stage trial, researchers consider them a significant step forward in addressing the limited treatment options for pancreatic cancer. The next steps will likely involve larger clinical trials to confirm efficacy and safety in broader patient populations.
As of now, no regulatory approvals have been granted for NP137, and the treatment remains investigational. Patients interested in participating in future studies should consult with oncology specialists or check clinical trial registries such as ClinicalTrials.gov for updates on upcoming phases of research.
This development adds to a growing effort to innovate in pancreatic cancer treatment, which has seen limited progress over the past decades. Other experimental approaches being explored include targeted therapies, immunotherapies, and novel drug delivery systems, though none have yet transformed the prognosis for most patients.
The research underscores the importance of basic science in uncovering novel therapeutic targets. By focusing on the molecular mechanisms of treatment resistance, scientists aim to develop smarter, more effective combinations that can outmaneuver cancer’s adaptive defenses.
For now, the focus remains on validating these early results through rigorous clinical investigation. The scientific community awaits further data to determine whether netrin-1 inhibition can become a viable component of future pancreatic cancer treatment strategies.
Stay informed about advances in cancer research by following updates from trusted medical journals and clinical trial registries. Share this article to help spread awareness of ongoing efforts to improve outcomes for patients facing challenging diagnoses.